Market Closed -
Euronext Paris
11:35:11 2024-06-07 am EDT
|
5-day change
|
1st Jan Change
|
0.098
EUR
|
-12.66%
|
|
-31.94%
|
-95.10%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
-
|
-
|
-
|
-
|
-
|
0.000278
|
Enterprise Value (EV)
1 |
-
|
-
|
-
|
-
|
-
|
-0.2362
|
P/E ratio
|
-
|
-
|
-
|
-
|
-
|
-0.08
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
0
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-0.44
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
0.04
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
0.05
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
1,950%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
0.01
x
|
Nbr of stocks (in thousands)
|
-
|
-
|
-
|
-
|
-
|
0.14
|
Reference price
2 |
16,240,000
|
4,640,000
|
2,416,000
|
40,000
|
336,000
|
2.000
|
Announcement Date
|
4/29/19
|
4/30/20
|
6/29/21
|
5/2/22
|
4/30/23
|
4/30/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.007
|
0.0952
|
0.031
|
0.0225
|
0.001112
|
0.5334
|
EBITDA
1 |
-13.02
|
-8.118
|
-3.437
|
-7.728
|
-6.294
|
-6.06
|
EBIT
1 |
-13.08
|
-8.175
|
-3.492
|
-7.828
|
-6.445
|
-6.908
|
Operating Margin
|
-186,852.84%
|
-8,590.87%
|
-11,281.43%
|
-34,725.65%
|
-579,583.27%
|
-1,294.97%
|
Earnings before Tax (EBT)
1 |
-13.56
|
-9.302
|
-6.684
|
-12.48
|
-4.346
|
-9.62
|
Net income
1 |
-10.78
|
-7.548
|
-6.143
|
-11.84
|
-3.549
|
-8.743
|
Net margin
|
-154,006.91%
|
-7,932.63%
|
-19,846.4%
|
-52,512.21%
|
-319,109.98%
|
-1,639.16%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-24.86
|
Free Cash Flow
1 |
-11.26
|
-6.032
|
-2.054
|
-3.701
|
-3.496
|
-4.607
|
FCF margin
|
-160,809.06%
|
-6,339.21%
|
-6,635%
|
-16,418.4%
|
-314,371.22%
|
-863.68%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/19
|
4/30/20
|
6/29/21
|
5/2/22
|
4/30/23
|
4/30/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1.35
|
1.23
|
9.68
|
32.1
|
5.55
|
0.24
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-11.3
|
-6.03
|
-2.05
|
-3.7
|
-3.5
|
-4.61
|
ROE (net income / shareholders' equity)
|
-606%
|
-287%
|
-88.7%
|
-43.1%
|
-7.54%
|
-17.7%
|
ROA (Net income/ Total Assets)
|
-85.2%
|
-68.7%
|
-20.6%
|
-15.8%
|
-7.76%
|
-8.01%
|
Assets
1 |
12.65
|
10.98
|
29.78
|
75.11
|
45.74
|
109.2
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
139.0
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
2.520
|
Capex
1 |
0.01
|
0
|
0.21
|
0.35
|
0.15
|
0.2
|
Capex / Sales
|
143.6%
|
2.47%
|
668.63%
|
1,547.6%
|
13,736.33%
|
38.13%
|
Announcement Date
|
4/29/19
|
4/30/20
|
6/29/21
|
5/2/22
|
4/30/23
|
4/30/24
|
|
1st Jan change
|
Capi.
|
---|
| -95.10% | 37.25K | | +51.85% | 57.87B | | +41.42% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|